🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re often tempted to believe that diagnosing a recurrence earlier will improve outcomes. Clinical trials, however, suggest the opposite. We need new studies, with new tools (eg ctDNA) & implementation of new treatments. But we also need to inform pts adequately on this topic.

🚨 #ESSO44 Abstract Submission ends in 2️⃣ weeks. 🔬 Share your work & join us in Gothenburg, SE ❌ 13 May 👉 esso44.org OncoAlert IR Roger Olofsson Bagge Eduard-Alexandru Bonci Andreas Brandl Gabrielle van Ramshorst, MD FECSM FEBS FSSO Wim Ceelen Dana Sochorova Cristina Dopazo Kjetil Søreide Florian Primavesi

Featured: Prognostic Value of Nevus-Associated Melanoma in Patients with Melanoma. Roger Olofsson Bagge ow.ly/iXU550VKT4y @jeffreyfarma Syed A. Ahmad

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt. Compared to 40Gy/15, 26Gy/5: 1. Non inf for IBR (even superior?) 2. Similar recurrence free interval, breast cancer interval, OS 3. No diff in PRO or toxicity Clearly 26/5 SOC for

May Issue: Identification of Predictive Factors for the Development of In-Transit Metastasis in Patients with #Melanoma . Roger Olofsson Bagge Cristina O’Donoghue J. Harrison Howard, MD MarkFariesMD Jonathan Zager, MD rdcu.be/ekVZg Dorian Y. García-Ortega MD, MSc,PhD, FACS Syed A. Ahmad

🎉 #ESSO44 has received 876 abstracts from colleagues around the world! Thank you to everyone who submitted. We can’t wait to see you in Gothenburg this October! More on the ESSO Congress at 👉 esso44.org

Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/4jePW1F

Important real-world data on early adoption of #neoadjuvant #immunotherapy for patients with melanoma in #Sweden. Similar beneficial efficacy and safety outcomes to those seen in clinical trials. sciencedirect.com/science/articl…

x.com/i/article/1929…

Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive! Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival.

First randomized trial testing circadian rhythm and time of immunotherapy administration show impressive results and some biological correlates open a research field in this setting #ASCO25 ⁦OncoAlert⁩

Another agent hopefully being added soon to our growing uveal melanoma arsenal, first results of the ADC GQ/11 direct inhibitor. Promising responses and very little toxicity. #ASCO25

The censoring "alert" in CHALLENGE is further supported by the reverse Kaplan-Meier analysis where each event is artificially modified into a censoring event, and vice-versa: the KM curves are displayed and a Cox analysis is performed. If a statistical difference is seen (HR,

Great presentation by Tina J Hieken MD on the promising results of the NEOACTIVATE arm C trial of anti TIGIT + anti PDL1 for clinical stage III melanoma. Correlative studies to follow in hope of identifying predictive biomarkers for better treatment tailoring. #ASCO25 Stand Up To Cancer Mayo Clinic

The power of placebo in 5 experiments (🧵) 1. Placebo improves symptoms in IBS - even if people know it's placebo Placebo was presented as "placebo pills, an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS”

Maybe this is a dumb question but aren’t the long half life antibodies still there the next morning?

In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.

A great read ⁦Journal of Clinical Oncology⁩ on the abscopal effect, which I, haven’t seen materialize in clinical practice! SBRT+anti–PD-1 didn’t improve outcomes in HNSCC. Abscopal responses are inconsistent! ⁦LARVOL⁩ ⁦OncoAlert⁩ ⁦⁦OncoDaily⁩ ascopubs.org/doi/10.1200/JC…

Highly anticipated mouse model of uveal melanoma (UM). Chr 8 amplification is a hallmark of metastatic uveal melanoma and MYC on that chromosome is now shown to augment tumorigenesis and metastasis of uveal melanoma in genetically engineered mouse model of UM.

The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes) American Heart Association